Efficacy and Safety of Benralizumab in EGPA Compared to Mepolizumab. (MANDARA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT04157348

Recruitment Status : Active, not recruiting

First Posted : November 8, 2019

Last Update Posted : April 25, 2024

View this study on the modernized ClinicalTrials.gov

Sponsor:

Information provided by (Responsible Party):

AstraZeneca

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Active, not recruiting
Actual Primary Completion Date :	August 10, 2023
Estimated Study Completion Date :	March 31, 2026

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Serling-Boyd N, Wallace ZS. Management of primary vasculitides with biologic and novel small molecule medications. Curr Opin Rheumatol. 2021 Jan;33(1):8-14. doi: 10.1097/BOR.0000000000000756.

To Top